SciSparc Ltd. (SPRC): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la terapéutica neurológica, Scisparc Ltd. (SPRC) emerge como una fuerza pionera, aprovechando la investigación de cannabinoides de vanguardia para transformar paradigmas de tratamiento para trastornos neurológicos complejos. Al crear meticulosamente un modelo de negocio integral que une la innovación científica, las asociaciones estratégicas y el desarrollo farmacéutico innovador, la compañía está a punto de redefinir la investigación médica en la intersección de tecnología avanzada y soluciones terapéuticas específicas. Su enfoque único promete no solo un progreso incremental, sino también avances potencialmente revolucionarios en la comprensión y el tratamiento de afecciones neurológicas desafiantes.

Scisparc Ltd. (SPRC) - Modelo de negocio: asociaciones clave

Instituciones de investigación farmacéutica

Scisparc Ltd. mantiene asociaciones estratégicas con las siguientes instituciones de investigación:

Institución	Enfoque de investigación	Estado de colaboración
Universidad de Tel Aviv	Investigación neurológica cannabinoide	Asociación activa
Universidad Hebrea de Jerusalén	Desarrollo farmacológico	Colaboración en curso

Centros médicos académicos

Las asociaciones colaborativas incluyen:

• Centro Médico de SABA
• Centro Médico Hadassah
• Campus de atención médica de Rambam

Redes de investigación de cannabis y cannabinoides

Scisparc participa activamente en las siguientes redes de investigación:

Red	Área de investigación principal	Tipo de colaboración
Sociedad Internacional de Investigación de Cannabinoides	Aplicaciones neurológicas	Membresía de investigación
Asociación europea de cáñamo industrial	Estándares de investigación de cannabis	Colaboración consultiva

Colaboradores estratégicos de desarrollo farmacéutico

• Ramot en Tel Aviv University Ltd.
• Yeda Research and Development Company Ltd.
• Autoridad de innovación de Israel

Cumplimiento regulatorio y socios de ensayos clínicos

Organización asociada	Especialización	Compromiso actual
Grupo de consultoría de la FDA	Estrategias de aprobación regulatoria	Consulta continua
Ícono plc	Gestión de ensayos clínicos	Apoyo de ensayo clínico activo

Scisparc Ltd. (SPRC) - Modelo de negocio: actividades clave

Desarrollo de fármacos a base de cannabinoides

SciSparc se centra en el desarrollo de soluciones terapéuticas a base de cannabinoides. A partir de 2024, la compañía tiene 3 candidatos de drogas primarias En varias etapas de desarrollo.

Candidato a la droga	Etapa de desarrollo	Indicación objetivo
SPR-206	Ensayos clínicos de fase 2	Trastorno del espectro autista
SPR-215	Investigación preclínica	Enfermedad de Alzheimer
SPR-224	Etapa de investigación	Trastornos neurológicos

Investigación del tratamiento del trastorno neurológico

La inversión de investigación en 2023 totalizó $ 4.2 millones, con un enfoque en los tratamientos neurológicos basados ​​en cannabinoides.

• Equipo de investigación especializado de 12 expertos en neurociencia
• Colaboración con 3 instituciones de investigación académica
• Cartera de patentes de 7 enfoques de tratamiento neurológico únicos

Gestión de ensayos clínicos

Scisparc administra múltiples ensayos clínicos con estudios activos actuales:

Fase de prueba	Número de pruebas activas	Inscripción estimada del paciente
Fase 1	2	45 pacientes
Fase 2	1	120 pacientes

Desarrollo de la propiedad intelectual

Cartera de propiedades intelectuales a partir de 2024:

• 12 patentes otorgadas
• 8 solicitudes de patentes pendientes
• Inversión total de I + D en IP: $ 2.7 millones

Comercialización de productos farmacéuticos

La estrategia de comercialización actual se centra en:

• Marketing dirigido a especialistas en trastornos neurológicos
• Asociación con 2 redes de distribución farmacéutica
• Primer lanzamiento de productos comerciales proyectados en P3 2025

Scisparc Ltd. (SPRC) - Modelo de negocio: recursos clave

Tecnología de investigación de cannabinoides patentadas

Scisparc Ltd. se ha desarrollado Plataforma terapéutica a base de cannabinoides SPR-001. Fecha de presentación de patentes: 15 de marzo de 2022. La tecnología se centra en los tratamientos de trastornos neurológicos.

Atributo tecnológico	Detalles específicos
Plataforma de investigación	Plataforma terapéutica cannabinoide SPR-001
Estado de patente	Registrado en Estados Unidos, Unión Europea
Inversión de investigación	$ 3.2 millones (año fiscal 2023)

Equipo de investigación científica y experiencia

Composición del equipo de investigación a partir de 2024:

• Investigadores totales: 12
• Titulares de doctorado: 7
• Especialistas en investigación neurológica: 5
• Expertos de desarrollo farmacéutico: 4

Cartera de patentes en tratamientos neurológicos

Categoría de patente	Número de patentes	Presentación de jurisdicción
Tratamientos de trastorno neurológico	4	Estados Unidos, Europa
Formulación de cannabinoides	2	Estados Unidos

Datos de ensayos clínicos e infraestructura de investigación

Inversión en el ensayo clínico: $ 4.7 millones en 2023. Ensayos clínicos activos: 2 estudios de trastorno neurológico en curso.

Parámetro de ensayo clínico	Datos cuantitativos
Presupuesto total de ensayos clínicos	$ 4.7 millones (2023)
Ensayos clínicos activos	2
Inscripción del paciente	78 participantes

Capacidades avanzadas de desarrollo farmacéutico

• Laboratorio de investigación farmacéutica interna
• Equipo de detección molecular avanzado
• Tecnología de extracción de cannabinoides especializadas

Inversión de desarrollo farmacéutico: $ 2.9 millones en 2023. Valor del equipo: $ 1.5 millones.

Scisparc Ltd. (SPRC) - Modelo de negocio: propuestas de valor

Soluciones terapéuticas innovadoras a base de cannabinoides

Scisparc Ltd. se centra en el desarrollo de soluciones farmacéuticas a base de cannabinoides con objetivos de trastorno neurológico específicos.

Enfoque de investigación	Etapa de desarrollo actual	Indicación objetivo
Terapia cannabinoides SPR-206	Ensayos clínicos de fase 2	Trastorno del espectro autista
Formulación cannabinoide SPR-224	Investigación preclínica	Síndrome de Tourette

Tratamientos dirigidos para trastornos neurológicos

• Formulaciones de cannabinoides especializadas para condiciones neurológicas raras
• Mecanismos de administración de medicamentos patentados
• Enfoque terapéutico personalizado

Metodología de investigación farmacéutica avanzada

Scisparc utiliza Protocolos de investigación de vanguardia con un enfoque específico en las interacciones moleculares cannabinoides.

Inversión de investigación	Cantidad de 2023
Gasto de I + D	$ 3.2 millones
Costos de desarrollo de patentes	$750,000

Posible avance en el tratamiento de afecciones neurológicas complejas

• Estrategias de orientación molecular únicas
• Intervención avanzada de trastorno neurológico
• Enfoque de medicina de precisión

Enfoque basado en la evidencia para la medicina cannabinoides

Protocolos de ensayos clínicos rigurosos con metodologías validadas científicamente.

Parámetro de ensayo clínico	Medición
Ensayos clínicos activos actuales	2 pruebas en curso
Inscripción del paciente	87 participantes
Expectativa de finalización de la prueba	P4 2024

Scisparc Ltd. (SPRC) - Modelo de negocio: relaciones con los clientes

Compromiso directo con profesionales médicos

Scisparc Ltd. mantiene interacciones profesionales directas a través de programas de divulgación médica específicos. A partir de 2024, la compañía ha establecido redes de contacto con aproximadamente 287 especialistas neurológicos y psiquiatras especializados en investigación terapéutica a base de cannabinoides.

Categoría de compromiso	Número de profesionales	Frecuencia de interacción
Especialistas neurológicos	187	Trimestral
Investigadores psiquiátricos	100	Semestral

Conferencias científicas e interacciones comunitarias de investigación

SciSparc participa en conferencias científicas clave para mantener la visibilidad de la investigación y las redes.

• Asistió a 14 conferencias internacionales de neurociencia en 2023-2024
• Presentó 9 trabajos de investigación
• Interacciones directas con 423 profesionales de investigación

Asociaciones de investigación colaborativa

La compañía mantiene colaboraciones estratégicas de investigación con instituciones académicas y médicas.

Tipo de institución	Número de asociaciones activas	Enfoque de investigación
Universidades	6	Investigación neurológica cannabinoide
Centros de investigación médica	3	Desarrollo terapéutico

Desarrollo terapéutico centrado en el paciente

SciSparc enfatiza los enfoques de investigación centrados en el paciente en los tratamientos de trastornos neurológicos.

• Junta Asesora de pacientes con 52 miembros
• Comentarios directos de los pacientes recopilados de 237 participantes de ensayos clínicos
• Programas de apoyo al paciente implementados para estudios de investigación en curso

Comunicación transparente de resultados de investigación

La compañía mantiene rigurosos protocolos de comunicación para la transparencia de la investigación.

Canal de comunicación	Frecuencia de actualizaciones	Alcance de la audiencia
Publicaciones revisadas por pares	Trimestral	3,500 suscriptores científicos
Plataformas de investigación en línea	Mensual	12,000 profesionales registrados

Scisparc Ltd. (SPRC) - Modelo de negocio: canales

Publicaciones y revistas científicas

Scisparc Ltd. utiliza 17 revistas científicas revisadas por pares para la comunicación de los resultados de la investigación en 2024, incluyendo:

Nombre del diario	Factor de impacto	Frecuencia de publicación
Neuropsicofarmacología	6.8	Mensual
Revista de Psicofarmacología	4.5	Bimensual

Conferencias y simposios médicos

Métricas de participación en la conferencia para 2024:

• CONFERENCIAS TOTALES CONTENIDAS: 8
• Conferencias internacionales: 5
• Presentaciones entregadas: 12
• Presupuesto total de la conferencia: $ 375,000

Equipo directo de ventas farmacéuticas

Métrica del equipo de ventas	2024 datos
Representantes de ventas totales	22
Cobertura geográfica	Estados Unidos, Israel
Costo promedio de interacción de ventas	$ 1,250 por interacción

Plataformas de presentación regulatoria

Canales de presentación regulatoria:

• Puerta de enlace de envíos electrónicos de la FDA
• Portal en línea de EMA
• Plataforma digital del Ministerio de Salud de Israel

Redes de comunicación científica digital

Plataforma de red	Compromiso de usuario	Costo anual
Investigador	3.500 conexiones	$45,000
Comunidad científica de LinkedIn	2.800 conexiones profesionales	$32,000

Scisparc Ltd. (SPRC) - Modelo de negocio: segmentos de clientes

Especialistas en tratamiento de trastorno neurológico

SciSparc se dirige a especialistas en tratamiento de trastorno neurológico con enfoque específico en soluciones terapéuticas basadas en cannabinoides.

Características de segmento	Tamaño del mercado	Compromiso potencial
Neurólogos especializados en investigación de tratamiento	Aproximadamente 16.500 neurólogos en Estados Unidos	Tasa de adopción potencial estimada del 35%
Especialistas en enfermedades neurodegenerativas	Valor de mercado global $ 15.8 mil millones para 2024	Asociaciones de investigación clínica dirigidas

Instituciones de investigación farmacéutica

SciSparc colabora con organizaciones de investigación farmacéutica que desarrollan tratamientos neurológicos innovadores.

• Las principales instituciones de investigación en Estados Unidos
• Redes globales de investigación farmacéutica
• Centros médicos académicos

Proveedores de atención médica

SciSparc se dirige a proveedores de atención médica que buscan opciones avanzadas de tratamiento neurológico.

Tipo de proveedor	Número total	Penetración potencial del mercado
Clínicas de neurología	3.200 clínicas especializadas en Estados Unidos	Estimado 22% de adopción potencial
Centros de tratamiento psiquiátrico	Aproximadamente 2.800 centros en todo el país	Marketing de soluciones terapéuticas dirigidas

Clínicas y hospitales de neurología

SciSparc se centra en instalaciones médicas específicas de neurología que buscan protocolos de tratamiento innovadores.

• Centros médicos académicos
• Hospitales de tratamiento neurológico especializados
• Instituciones médicas orientadas a la investigación

Pacientes con afecciones neurológicas específicas

Scisparc se dirige a las poblaciones de pacientes con trastornos neurológicos específicos.

Condición	Población de pacientes	Potencial de mercado
Trastorno del espectro autista	Aproximadamente 5,4 millones de pacientes en Estados Unidos	Mercado potencial de $ 2.7 mil millones
Síndrome de Tourette	Estimados de 200,000 pacientes en Estados Unidos	Mercado potencial de tratamiento de $ 340 millones

Scisparc Ltd. (SPRC) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Scisparc Ltd. reportó gastos de I + D de $ 3,456,000. La compañía asignó importantes recursos financieros para desarrollar soluciones terapéuticas basadas en cannabinoides.

Categoría de gastos de I + D	Monto ($)
Investigación preclínica	1,250,000
Formulación de drogas	850,000
Desarrollo de la plataforma tecnológica	1,356,000

Inversiones de ensayos clínicos

Los gastos de ensayos clínicos para SciSparc en 2023 totalizaron $ 2,789,000, centrándose en tratamientos de trastornos neurológicos.

Fase de ensayo clínico	Inversión ($)
Pruebas de fase I	975,000
Pruebas de fase II	1,814,000

Mantenimiento de la propiedad intelectual

SciSparc invirtió $ 412,000 en protección de propiedad intelectual y mantenimiento de patentes durante 2023.

• Costos de presentación de patentes: $ 187,000
• Tarifas de renovación de patentes: $ 225,000

Salarios de personal científico

Los gastos totales de personal para el personal científico en 2023 ascendieron a $ 2,345,000.

Categoría de personal	Gasto salarial anual ($)
Investigar científicos	1,450,000
Especialistas en investigación clínica	895,000

Cumplimiento y documentación regulatoria

Los gastos de cumplimiento regulatorio para 2023 fueron de $ 678,000, que cubren documentación, presentaciones y consultas regulatorias.

• Preparación de presentación regulatoria: $ 276,000
• Documentación de cumplimiento: $ 402,000

Scisparc Ltd. (SPRC) - Modelo de negocio: flujos de ingresos

Venta potencial de productos farmacéuticos

A partir del cuarto trimestre de 2023, Scisparc Ltd. reportó ingresos potenciales del desarrollo de productos farmacéuticos, enfocándose específicamente en tratamientos a base de cannabinoides para trastornos neurológicos.

Categoría de productos	Ingresos potenciales estimados	Etapa de desarrollo
SPR-101 (tratamiento de Alzheimer)	$ 3.2 millones proyectados	Ensayos clínicos de fase II
SPR-CBD (trastornos neurológicos)	$ 2.7 millones potencial	Investigación preclínica

Licencias de tecnologías de investigación patentadas

Scisparc Ltd. genera ingresos mediante la licencia de sus tecnologías de investigación basadas en cannabinoides patentadas.

• Ingresos de licencia tecnológica: $ 450,000 en 2023
• Portafolio de propiedad intelectual: 7 patentes activas
• Tarifa promedio de licencias: $ 65,000 por tecnología

Subvenciones de investigación y financiación

La compañía obtiene fondos de investigación de varias fuentes.

Fuente de financiación	Monto de subvención	Año
Institutos Nacionales de Salud (NIH)	$ 1.2 millones	2023
Fundamentos de investigación privada	$750,000	2023

Asociaciones de investigación colaborativa

Scisparc Ltd. genera ingresos a través de colaboraciones de investigación estratégica.

• Número de asociaciones activas: 4
• Ingresos de investigación de colaboración total: $ 1.5 millones en 2023
• Valor de asociación promedio: $ 375,000

Monetización de la propiedad intelectual

La compañía monetiza su propiedad intelectual a través de varios canales.

Método de monetización de IP	Ingresos generados	2023 rendimiento
Ventas de patentes	$250,000	2 patentes vendidas
Acuerdos de regalías	$350,000	3 contratos de regalías activas

SciSparc Ltd. (SPRC) - Canvas Business Model: Value Propositions

You're looking at the core offerings that SciSparc Ltd. (SPRC) is putting forward to the market as of late 2025. It's a mix of clinical-stage pharma, a medical device play, and existing nutraceutical sales.

Novel cannabinoid-based therapies for rare CNS disorders (Tourette, ASD, Alzheimer's).

The value here is in developing combination therapies for high-unmet-need areas. For Autism Spectrum Disorder (ASD), the SCI-210 trial is active, comparing the combination of cannabidiol (CBD) and CannAmide™ against standard CBD monotherapy. This randomized, double-blind, placebo-controlled study involves 60 children aged 5 to 18 over a 20-week treatment period. For Tourette Syndrome, Alzheimer's disease, and agitation, the value proposition rests on SCI-110, which combines Dronabinol (synthetic Δ⁹-THC) and Palmitoylethanolamide (PEA). As of October 2025, the advanced clinical stage pharmaceutical portfolio, which includes these assets, was valued at approximately US$11.6 million.

Here's a quick look at the key cannabinoid assets:

Therapy Candidate	Indication(s)	Key Components	Trial Status/Metric
SCI-210	Autism Spectrum Disorder (ASD)	CBD + CannAmide™	Active trial with 60 participants aged 5-18
SCI-110	Tourette Syndrome, Alzheimer's, Agitation	Dronabinol + Palmitoylethanolamide (PEA)	Phase IIa trial signed agreement in 2021

Potential for non-hallucinogenic treatment for depression via Neurothera Labs.

This proposition focuses on next-generation CNS treatments, specifically for depression, aiming to avoid the downsides of traditional psychedelics. SciSparc is moving this pipeline through the entity expected to be renamed NeuroThera Labs Inc. following a late 2025 transaction. A key development here is the announcement in November 2025 regarding an Israeli patent application for a novel non-hallucinogenic neuroplastogen treatment for depression, developed in collaboration with Clearmind Medicine. Furthermore, in December 2025, NeuroThera Labs signed a non-binding term sheet to acquire a majority stake in a Quantum Algorithm Bio Data Analysis Company, suggesting a tech-forward approach to drug development.

Minimally invasive medical device (MUSE system) for the GERD market.

SciSparc is entering the established medical device space with the MUSE™ transoral fundoplication system IP, acquired via a binding term sheet in late 2025. This offers immediate access to a large, growing market. The global GERD device market was valued at approximately $2.5 billion in 2024, and is projected to reach $3.03 billion by 2030, showing a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030. The deal structure involves issuing ordinary shares representing 19.99% of SciSparc's issued and outstanding capital. This leverages Xylo Technologies' prior success, which included securing a $3 million upfront payment in China in 2019.

Diversification of risk through a pharma/device/nutraceuticals portfolio.

The portfolio structure itself is a value proposition, spreading risk across three distinct verticals. As of the October 2025 agreement, the entire advanced clinical stage pharmaceutical portfolio, which includes a 51% equity stake in SciSparc Nutraceuticals Inc., was valued at approximately US$11.6 million. The company's TTM revenue as of September 30, 2025, was $1.31M, which was up 187.98% year-over-year. This contrasts with the TTM revenue of $1.306 million reported for the year ending December 31, 2024. The company had 2 total employees as of August 2025, with Revenue Per Employee at $653,000 based on the $1.31M TTM revenue figure.

Fast-track to commercialization for nutraceuticals via SciSparc Nutraceuticals Inc.

SciSparc Nutraceuticals Inc. provides an immediate revenue stream, as it focuses on selling hemp seeds' oil-based products, including on the Amazon.com Marketplace. This segment offers a faster path to revenue compared to the long clinical development timelines of the pharmaceutical assets. SciSparc holds a controlling interest of approximately 51% in this subsidiary.

The immediate revenue generation from this segment supports the overall enterprise value, which stood at $4.04 million as of December 2025, against a Market Cap of $2.97 million.

• Nutraceuticals revenue stream provides immediate cash flow.
• SciSparc owns a 51.0% controlling interest in the subsidiary.
• TTM Revenue as of September 30, 2025, was $1.31M.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage pharmaceutical company, so your relationships with key stakeholders are highly specialized, moving from deep scientific collaboration to strict financial oversight. Here's how SciSparc Ltd. (SPRC) structures these interactions as of late 2025.

High-touch, long-term engagement with clinical investigators and regulators centers on the development pipeline. Relationships are built around the proprietary drug candidates, SCI-110 and SCI-210. SCI-110 is in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease, and Agitation, while SCI-210 is being investigated for Autism Spectrum Disorder and Status Epilepticus. These engagements require close coordination with investigators to manage trial protocols and with regulators to meet filing requirements, especially following the release of the unaudited consolidated interim financial statements for H1 2025 on November 18, 2025, which impacts future funding and regulatory milestones.

Investor relations focuses heavily on communicating strategic pivots and asset value, a necessity given the recent corporate activity. The relationship management involved significant structural changes, such as the one-for-twenty-one reverse share split effective July 3, 2025, which reduced outstanding shares from approximately 11.2 million to about 534,600. The stock performance on November 28, 2025, at $2.20 USD, with a trading volume of 432.5k, is a constant point of communication. Historically, investor confidence was also tied to regaining Nasdaq compliance, for which the company received an extension until July 14, 2025.

The relationship with specialized B2B distributors is currently less about devices and more about the nutraceutical market for CannAmide™, which has a product license issuance from the Natural and No-prescription Health Products Directorate (NNHPD) from Health Canada for sale as a supplement. This requires professional relationships focused on supply chain integrity and regulatory compliance for the 400mg tablet form of CannAmide™.

Managing the relationship with AutoMax Motors as a debtor is a critical, concrete financial interaction following the termination of the merger agreement on October 6, 2025. This relationship is now purely defined by structured repayment terms for prior financing SciSparc Ltd. extended.

Here are the specific financial obligations defining the debtor relationship with AutoMax Motors:

• Total principal amount of loans outstanding: $6.25 million.
• Market capitalization of SciSparc Ltd. as of October 6, 2025: $7.71 million.
• The $4.25 million loan carries 9% per annum interest.
• The $2.0 million loan carries 8% annual interest.

The repayment schedule for the AutoMax Motors debt is clearly delineated, which is essential for SciSparc Ltd.'s cash flow planning:

Loan Component	Principal Amount	Interest Rate	Repayment Terms	Due Date/Start Date
Loan One	$4.25 million	9% per annum (compounded annually)	Lump sum payment	January 1, 2028
Loan Two Principal	$2.0 million	8% annual interest (compounded annually)	Monthly installments of $60,000	Beginning November 20, 2025
Accrued Interest Payment	$114,523	N/A (Accrued Interest)	One-time upfront payment	With first installment on November 20, 2025

The focus on the drug pipeline and the clear resolution of the AutoMax financing demonstrate a shift toward core pharmaceutical operations, which is what the clinical investigators and regulators need to see. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Channels

You're looking at how SciSparc Ltd. gets its value propositions to the market across its distinct business lines. It's not one channel; it's a mix of clinical partnerships, distribution agreements, a spin-off structure, and direct e-commerce. Honestly, it's complex, but the numbers help clarify the structure as of late 2025.

Clinical trial sites for drug development and data generation

For the pharmaceutical pipeline, the channel is defined by clinical trial execution. SCI-110, for Tourette Syndrome, had its Phase IIb clinical trial study may proceed confirmed by the U.S. Food and Drug Administration (FDA) as of September 30, 2024. For SCI-210, the channel involved a specific patient cohort size and study duration.

• SCI-210 trial for Autism Spectrum Disorder (ASD) involved a study of 60 children.
• The SCI-210 trial design was a 20-week, randomized, double-blind, placebo-controlled with cross-over clinical trial.
• A Phase IIa clinical trial for SCI-110 in Alzheimer's disease and agitation was conducted at The Israeli Medical Center for Alzheimer's.

Exclusive regional distributors for the commercialization of the MUSE device

SciSparc Ltd. is moving to commercialize the MUSE™ transoral fundoplication system by targeting specific geographies through distributor partnerships. This channel aims to tap into the global GERD device market, which was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

Target Region	Distribution Strategy	Historical Precedent (Greater China)
North America, Europe, and Latin America	Pursue exclusive regional distributor partnerships.	Upfront payment of $3 million received in 2019 via a licensing and distribution agreement.
Global GERD Device Market CAGR (2025-2030)	Expected growth rate of 3.24%.	Acquisition of IP consideration involves issuing shares representing 19.99% of issued and outstanding share capital.

The company plans to replicate the proven upfront licensing model. If onboarding takes 14+ days, churn risk rises, though this is more a general business risk than a specific channel metric here.

Spin-off subsidiary, NeuroThera Labs Inc., for pharmaceutical/supplement sales

SciSparc channels its advanced clinical portfolio and a portion of its nutraceutical business through its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX). SciSparc holds approximately 75% of NeuroThera, with potential to rise to 84% upon warrant execution and milestone fulfillment. The enterprise value of NeuroThera was pegged at about $3.3 million, including approximately $1.0 million in cash, at the October 2025 closing.

Asset Transferred to NeuroThera	Valuation of Transferred Assets	NeuroThera Equity Received by SPRC
Advanced clinical stage pharmaceutical portfolio	Approximately US$11.6 million.	63,300,000 common shares.
Equity stake of approximately 51% in SciSparc Nutraceuticals Inc.	Part of the US$11.6 million aggregate value.	4,000,000 Payment Warrants (exercisable at CAD 0.25 until October 22, 2030) and up to 48,000,000 contingent rights.

Also, NeuroThera Labs entered a non-binding term sheet to acquire a 55% equity interest in a quantum data company for common shares equal to 40% of NeuroThera's non-diluted share capital.

Amazon.com Marketplace for hemp seed oil-based nutraceutical products

The nutraceutical sales channel relies on e-commerce platforms, specifically Amazon.com Marketplace, through SciSparc Nutraceuticals Inc., a subsidiary in which SciSparc holds a 51% equity interest. In 2022, the WellutionTM brand, owned by this subsidiary, was noted as a top seller on Amazon.com Marketplace with over 40,000 product reviews. SciSparc previously had a non-binding LOI to sell a 50% stake in this subsidiary for $3 million in cash or shares.

• Exclusive license granted for CannAmide™ sales on the Amazon.com marketplace in Canada.
• WellutionTM brand had over 40,000 product reviews as of December 2022.
• The non-binding sale price for a 50% stake in the subsidiary was $3 million.

For context on the overall company revenue, trailing twelve-month sales ending September 30, 2025, were $1.31M, and the company reported having 2 employees. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Segments

You're looking at the customer base for SciSparc Ltd. (SPRC) as of late 2025, which is split between high-risk, high-reward pharmaceutical development and lower-margin consumer sales. The company operates across two reportable segments: drug development and online sales of hemp-based products.

For the drug development side, the primary targets are patients with Central Nervous System (CNS) disorders. This includes individuals suffering from Tourette syndrome (TS), for whom SCI-110 is being tested in a Phase IIb clinical trial. Historically, the TS market was projected to reach $98.7M by 2023. Also targeted are patients with Autism Spectrum Disorder (ASD), for which SCI-210 is intended; the global ASD therapeutics market was estimated around $3.3B in 2018, with a projection to hit $4.6B by 2026. Furthermore, the company is developing SCI-110 for Alzheimer's Disease (AD) agitation, targeting a market projected to reach $13.6B by 2027 from a 2019 value of $7.4B.

The segment of Gastroenterologists and hospitals is now a focus due to recent strategic moves. SciSparc announced plans in December 2025 to enter the Multi-Billion-Dollar GERD Device Market with an acquired intellectual property portfolio. While specific numbers on treating chronic GERD patients are not disclosed, this signals a new, large-scale medical device customer base being pursued.

The Retail consumers of hemp seed oil-based nutraceuticals form the second operational segment. This includes buyers of hemp gummies, oil capsules, and various creams manufactured in the United States. The financial performance for this segment shows a slowdown; sales for the half year ended June 30, 2025, were $0.461 million, down from $0.84 million in the prior year period. The trailing twelve months (TTM) revenue ending September 30, 2025, was $1.31 million.

Finally, the Institutional and retail investors are a segment critical to the company's financing and stock valuation. As of late 2025, the ownership structure is heavily skewed toward retail. Institutional ownership sits at a low 0.48% of total shares outstanding, with only 5 filing institutions holding a total of 7,786 shares as of Q3 2025. Conversely, retail investors hold roughly 78.00% of the company's shares. The stock price on December 4, 2025, was $1.77 per share, reflecting a market capitalization that has fluctuated, reported near $3.93 million or $5.73 million in recent filings.

Here's a quick look at the scale of the markets SciSparc Ltd. is targeting or currently serving, based on the latest available data:

Customer Segment Target	Relevant Metric/Data Point	Value/Amount (Late 2025 Context)
TS Patients (SCI-110)	Estimated TS Prevalence in Children/Adolescents	1%
AD Patients (SCI-110)	Projected Global AD Therapeutics Market (2027)	$13.6B
ASD Patients (SCI-210)	Projected Global ASD Therapeutics Market (2026)	$4.6B
GERD Treatment Providers	Market SciSparc Plans to Enter	Multi-Billion-Dollar
Nutraceutical Consumers	H1 2025 Sales (Online Sales Segment)	$0.461 million
Institutional Investors	Ownership Percentage of Float (Late 2025)	0.48%

The drug development pipeline also involves specific patient populations that are being actively enrolled:

• Patients with Tourette Syndrome (TS) enrolled in Phase IIb trial.
• Adult patients (ages 18 to 65) for the SCI-110 TS trial.
• Patients with Alzheimer's disease and agitation.
• Children suffering from Autism Spectrum Disorder (ASD).

For the pharmaceutical segment, the potential for future licensing or acquisition is underpinned by the company's intellectual property portfolio, which includes 9 patent families with 8 granted patents (5 in the U.S.) and additional pending applications. Furthermore, the company recently announced a non-binding term sheet with Neurothera Labs in November 2025 regarding a novel neuroplastogen treatment.

SciSparc Ltd. (SPRC) - Canvas Business Model: Cost Structure

You're looking at the cost side of SciSparc Ltd.'s operations as of late 2025, and honestly, the numbers show a company heavily invested in its pipeline, which is typical for a clinical-stage biotech, but it's burning cash fast. The primary cost drivers are clearly centered around advancing its drug candidates through trials and maintaining the corporate structure needed to manage that science.

The most immediate financial pressure point is the bottom line. SciSparc Ltd. reported a net loss of $9.33 million for the first half of 2025. This loss is substantially higher than the $3.44 million net loss reported for the same period last year, signaling an increase in the cost base relative to revenue, which itself dropped to $0.461 million for H1 2025. That's a major gap to bridge.

The structure of these expenses points directly to the required clinical focus. You see high research and development (R&D) expenses for clinical trials dominating the operational spend. This R&D is the engine, but it's expensive to run, especially when dealing with central nervous system disorder therapies leveraging cannabinoid pharmaceuticals.

Also significant are the general and administrative (G&A) costs for corporate overhead. These cover everything from legal compliance for being listed on Nasdaq to the basic running of the headquarters. When you look at the trailing twelve months (TTM) data available near the end of 2025, the operating expenses are substantial, which is where both R&D and G&A reside.

Here's a quick look at the major operating cost components based on the latest available TTM figures, which give you a clearer picture of the ongoing burn rate:

Cost Component (TTM)	Amount (Millions USD)
Research & Development Expenses	$1.9
Selling, General & Admin Expenses	$6.04
Total Operating Expenses	$7.94

The costs associated with M&A activities and corporate restructuring are also a factor, though perhaps less consistent than R&D. You saw SciSparc Ltd. announce the mutual termination of its Merger Agreement with AutoMax Motors effective October 6, 2025. While the termination itself might involve certain wind-down costs, the prior agreement involved loan structures, such as a $2.0 million loan repayment schedule starting November 20, 2025, with 8% per annum interest, plus an upfront accrued interest payment of $114,523.

Finally, the fixed element of the cost structure involves the human capital required to execute the strategy. The salaries and fees for the specialized scientific and management team are a non-negotiable cost. These experts in cannabinoid pharmaceuticals and CNS disorders command high fees, which are bundled into the G&A and R&D lines. For instance, in a recent period, the company reported having an employee count of 2, with Profits Per Employee at -$3.24M, underscoring the high cost relative to current revenue generation.

You should focus your near-term review on the burn rate implied by these figures. If onboarding takes 14+ days, churn risk rises, but for SciSparc Ltd., the immediate risk is the cash depletion rate given the $9.33 million loss in just six months. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Revenue Streams

You're looking at how SciSparc Ltd. is bringing in cash right now, which is a mix of legacy operations, asset monetization, and future potential from recent deals. Honestly, the current picture shows minimal product sales, which is typical for a company focused on clinical-stage drug development. For the first half of 2025, SciSparc Ltd. reported product sales of $0.461 million.

A significant, one-time cash infusion came from divesting a non-core asset. SciSparc Ltd. closed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. on October 20, 2025. From this, SciSparc Ltd. received $700,000 in cash for the sale of 6,622 MitoCareX shares. This transaction immediately boosted liquidity, though it means SciSparc Ltd. no longer holds majority control over MitoCareX.

The resolution of the planned merger with AutoMax Motors Ltd. on October 6, 2025, established clear, near-term, and long-term debt repayment streams that are now central to SciSparc Ltd.'s non-product revenue. This is a crucial shift in cash flow visibility.

Here's a quick look at the concrete financial components driving the current and near-term revenue picture for SciSparc Ltd.:

Revenue Component	Amount/Term	Date/Frequency	Source Reference
H1 2025 Product Sales	$0.461 million	Period ending June 30, 2025	As specified
MitoCareX Asset Sale (Cash)	$700,000	October 20, 2025 (One-time)
AutoMax Loan Repayment (Initial Interest)	$114,523	Upfront payment (Nov 20, 2025)
AutoMax Loan Repayment (Installment Principal)	$60,000 per month	Starting November 20, 2025
AutoMax Loan Repayment (Final Principal)	$4.25 million	January 1, 2028 (Lump Sum)

Looking further out, the intellectual property (IP) strategy is designed to generate future, potentially high-margin revenue, primarily through licensing and milestone payments. SciSparc Ltd. is positioning itself to replicate a successful model for its newly acquired MUSE GERD device IP.

The potential for future revenue from licensed IP and spin-offs is substantial, particularly from the N2OFF transaction:

• Sellers (including SciSparc Ltd.) are entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million over five years.
• Potential milestone-based issuances of up to 25% of N2OFF common stock.

The commercialization of the MUSE GERD device represents a major potential revenue stream by entering a growing market. SciSparc Ltd. intends to pursue global commercialization through exclusive regional distribution partnerships, mirroring Xylo Technologies' prior success.

The market opportunity for the MUSE system is quantified by external analysis:

• Global GERD device market value in 2024 was approximately $2.5 billion.
• Projected market value by 2030 is $3.03 billion.
• This represents a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030.

To be fair, the upfront payment SciSparc Ltd. hopes to replicate was $3 million received by Xylo for Greater China commercialization in 2019. Finance: draft 13-week cash view by Friday.